CovidV1, Istex, Corpus, bibRecord, 000178

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Identifieur interne : 000178 ( Istex/Corpus ); précédent : 000177; suivant : 000179

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Auteurs : E. Lunell ; L. Molander ; M. Andersson

Source :

European Journal of Clinical Pharmacology [ 0031-6970 ] ; 1995-03-01.

RBID : ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C

English descriptors

Abstract

Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.

Url:

https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/fulltext.pdf

DOI: 10.1007/BF00202176

Links to Exploration step

ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
<author><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name>
<affiliation><mods:affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Department of Clinical Pharmacology, University Hospital, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name>
<affiliation><mods:affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name>
<affiliation><mods:affiliation>Department of Oto-rhino-laryngology, University Hospital, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1007/BF00202176</idno>
<idno type="url">https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000178</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000178</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
<author><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name>
<affiliation><mods:affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Department of Clinical Pharmacology, University Hospital, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name>
<affiliation><mods:affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name>
<affiliation><mods:affiliation>Department of Oto-rhino-laryngology, University Hospital, Lund, Sweden</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Clinical Pharmacology</title>
<title level="j" type="abbrev">Eur J Clin Pharmacol</title>
<idno type="ISSN">0031-6970</idno>
<idno type="eISSN">1432-1041</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="1995-03-01">1995-03-01</date>
<biblScope unit="volume">48</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="71">71</biblScope>
<biblScope unit="page" to="75">75</biblScope>
</imprint>
<idno type="ISSN">0031-6970</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0031-6970</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nicotine</term>
<term>Rhinitis</term>
<term>drug interaction</term>
<term>nasal spray</term>
<term>pharmacokinetics</term>
<term>xylometazoline</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adverse events</term>
<term>Baseline nicotine concentration</term>
<term>Bioavailability</term>
<term>Bioequivalence</term>
<term>Bioequivalence ranges</term>
<term>Blood flow</term>
<term>Blood samples</term>
<term>Clin pharmacokinet</term>
<term>Cmax</term>
<term>Concurrent administration</term>
<term>Confidence intervals</term>
<term>Decongestant</term>
<term>Drug administration</term>
<term>First dose</term>
<term>Infectious rhinitis</term>
<term>Intranasal</term>
<term>Intranasal administration</term>
<term>Intranasal nicotine</term>
<term>Minor proportion</term>
<term>Minor reduction</term>
<term>Nasal</term>
<term>Nasal cavity</term>
<term>Nasal discharge</term>
<term>Nasal mucosa</term>
<term>Nasal mucosal blood flow</term>
<term>Nasal nicotine solution</term>
<term>Nasal obstruction</term>
<term>Nasal spray</term>
<term>Nasal vasoconstrictor decongestant</term>
<term>Nicotine</term>
<term>Nicotine absorption</term>
<term>Nicotine behaviour</term>
<term>Nicotine patch</term>
<term>Normal health</term>
<term>Peak concentration</term>
<term>Peak plasma concentration</term>
<term>Pharmacokinetic</term>
<term>Plasma curve</term>
<term>Present study</term>
<term>Rapid absorption</term>
<term>Rhinitis</term>
<term>Rhinitis rhinitis</term>
<term>Rhinitis xylometazoline</term>
<term>Smoking cessation</term>
<term>Smoking cessation products</term>
<term>Tmax</term>
<term>Topical decongestant</term>
<term>University hospital</term>
<term>Vasoconstrictor</term>
<term>Vasoconstrictor xylometazoline</term>
<term>Xylometazoline</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</div>
</front>
</TEI>
<istex><corpusName>springer-journals</corpusName>
<keywords><teeft><json:string>nicotine</json:string>
<json:string>rhinitis</json:string>
<json:string>xylometazoline</json:string>
<json:string>decongestant</json:string>
<json:string>vasoconstrictor</json:string>
<json:string>tmax</json:string>
<json:string>bioavailability</json:string>
<json:string>nasal</json:string>
<json:string>pharmacokinetic</json:string>
<json:string>nasal spray</json:string>
<json:string>cmax</json:string>
<json:string>bioequivalence</json:string>
<json:string>topical decongestant</json:string>
<json:string>nasal discharge</json:string>
<json:string>nasal mucosa</json:string>
<json:string>intranasal</json:string>
<json:string>baseline nicotine concentration</json:string>
<json:string>rhinitis rhinitis</json:string>
<json:string>nasal mucosal blood flow</json:string>
<json:string>nasal cavity</json:string>
<json:string>present study</json:string>
<json:string>smoking cessation</json:string>
<json:string>university hospital</json:string>
<json:string>intranasal nicotine</json:string>
<json:string>normal health</json:string>
<json:string>peak concentration</json:string>
<json:string>nasal obstruction</json:string>
<json:string>drug administration</json:string>
<json:string>vasoconstrictor xylometazoline</json:string>
<json:string>rapid absorption</json:string>
<json:string>blood samples</json:string>
<json:string>first dose</json:string>
<json:string>nicotine patch</json:string>
<json:string>peak plasma concentration</json:string>
<json:string>plasma curve</json:string>
<json:string>smoking cessation products</json:string>
<json:string>nicotine behaviour</json:string>
<json:string>rhinitis xylometazoline</json:string>
<json:string>intranasal administration</json:string>
<json:string>confidence intervals</json:string>
<json:string>bioequivalence ranges</json:string>
<json:string>nicotine absorption</json:string>
<json:string>minor proportion</json:string>
<json:string>adverse events</json:string>
<json:string>nasal vasoconstrictor decongestant</json:string>
<json:string>concurrent administration</json:string>
<json:string>infectious rhinitis</json:string>
<json:string>blood flow</json:string>
<json:string>clin pharmacokinet</json:string>
<json:string>nasal nicotine solution</json:string>
<json:string>minor reduction</json:string>
</teeft>
</keywords>
<author><json:item><name>E. Lunell</name>
<affiliations><json:string>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</json:string>
<json:string>Department of Clinical Pharmacology, University Hospital, Lund, Sweden</json:string>
</affiliations>
</json:item>
<json:item><name>L. Molander</name>
<affiliations><json:string>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</json:string>
</affiliations>
</json:item>
<json:item><name>M. Andersson</name>
<affiliations><json:string>Department of Oto-rhino-laryngology, University Hospital, Lund, Sweden</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>Nicotine</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Rhinitis</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>pharmacokinetics</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>nasal spray</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>xylometazoline</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>drug interaction</value>
</json:item>
</subject>
<articleId><json:string>BF00202176</json:string>
<json:string>Art14</json:string>
</articleId>
<arkIstex>ark:/67375/1BB-PJ4Q91WT-1</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>OriginalPaper</json:string>
</originalGenre>
<abstract>Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</abstract>
<qualityIndicators><score>7.323</score>
<pdfWordCount>2947</pdfWordCount>
<pdfCharCount>17290</pdfCharCount>
<pdfVersion>1.3</pdfVersion>
<pdfPageCount>5</pdfPageCount>
<pdfPageSize>594 x 785 pts</pdfPageSize>
<refBibsNative>false</refBibsNative>
<abstractWordCount>198</abstractWordCount>
<abstractCharCount>1330</abstractCharCount>
<keywordCount>6</keywordCount>
</qualityIndicators>
<title>Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
<pmid><json:string>7542589</json:string>
</pmid>
<genre><json:string>research-article</json:string>
</genre>
<host><title>European Journal of Clinical Pharmacology</title>
<language><json:string>unknown</json:string>
</language>
<publicationDate>1995</publicationDate>
<copyrightDate>1995</copyrightDate>
<issn><json:string>0031-6970</json:string>
</issn>
<eissn><json:string>1432-1041</json:string>
</eissn>
<journalId><json:string>228</json:string>
</journalId>
<volume>48</volume>
<issue>1</issue>
<pages><first>71</first>
<last>75</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Pharmacology/Toxicology</value>
</json:item>
</subject>
</host>
<namedEntities><unitex><date></date>
<geogName></geogName>
<orgName></orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName></persName>
<placeName></placeName>
<ref_url></ref_url>
<ref_bibl></ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/1BB-PJ4Q91WT-1</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - pharmacology & pharmacy</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - pharmacology & pharmacy</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Pharmacology (medical)</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string>
<json:string>3 - Pharmacology</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - General Medicine</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
<json:string>4 - otorhinolaryngologie. stomatologie</json:string>
</inist>
</categories>
<publicationDate>1995</publicationDate>
<copyrightDate>1995</copyrightDate>
<doi><json:string>10.1007/BF00202176</json:string>
</doi>
<id>7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<availability><licence><p>Springer-Verlag, 1995</p>
</licence>
<p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p>
</availability>
<date>1994-05-20</date>
</publicationStmt>
<notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
<note>Pharmacoepidemiology and Disposition</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
<author xml:id="author-0000" corresp="yes"><persName><forename type="first">E.</forename>
<surname>Lunell</surname>
</persName>
<affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</affiliation>
<affiliation>Department of Clinical Pharmacology, University Hospital, Lund, Sweden</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">L.</forename>
<surname>Molander</surname>
</persName>
<affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">M.</forename>
<surname>Andersson</surname>
</persName>
<affiliation>Department of Oto-rhino-laryngology, University Hospital, Lund, Sweden</affiliation>
</author>
<idno type="istex">7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C</idno>
<idno type="ark">ark:/67375/1BB-PJ4Q91WT-1</idno>
<idno type="DOI">10.1007/BF00202176</idno>
<idno type="article-id">BF00202176</idno>
<idno type="article-id">Art14</idno>
</analytic>
<monogr><title level="j">European Journal of Clinical Pharmacology</title>
<title level="j" type="abbrev">Eur J Clin Pharmacol</title>
<idno type="pISSN">0031-6970</idno>
<idno type="eISSN">1432-1041</idno>
<idno type="journal-ID">true</idno>
<idno type="issue-article-count">20</idno>
<idno type="volume-issue-count">6</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="1995-03-01"></date>
<biblScope unit="volume">48</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="71">71</biblScope>
<biblScope unit="page" to="75">75</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>1994-05-20</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>Key words</head>
<item><term>Nicotine</term>
</item>
<item><term>Rhinitis</term>
</item>
<item><term>pharmacokinetics</term>
</item>
<item><term>nasal spray</term>
</item>
<item><term>xylometazoline</term>
</item>
<item><term>drug interaction</term>
</item>
</list>
</keywords>
</textClass>
<textClass><keywords scheme="Journal Subject"><list><head>Biomedicine</head>
<item><term>Pharmacology/Toxicology</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="1994-05-20">Created</change>
<change when="1995-03-01">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType>
<istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName>
<PublisherLocation>Berlin/Heidelberg</PublisherLocation>
</PublisherInfo>
<Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>228</JournalID>
<JournalPrintISSN>0031-6970</JournalPrintISSN>
<JournalElectronicISSN>1432-1041</JournalElectronicISSN>
<JournalTitle>European Journal of Clinical Pharmacology</JournalTitle>
<JournalAbbreviatedTitle>Eur J Clin Pharmacol</JournalAbbreviatedTitle>
<JournalSubjectGroup><JournalSubject Type="Primary">Biomedicine</JournalSubject>
<JournalSubject Type="Secondary">Pharmacology/Toxicology</JournalSubject>
</JournalSubjectGroup>
</JournalInfo>
<Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>48</VolumeIDStart>
<VolumeIDEnd>48</VolumeIDEnd>
<VolumeIssueCount>6</VolumeIssueCount>
</VolumeInfo>
<Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>1</IssueIDStart>
<IssueIDEnd>1</IssueIDEnd>
<IssueArticleCount>20</IssueArticleCount>
<IssueHistory><CoverDate><Year>1995</Year>
<Month>3</Month>
</CoverDate>
</IssueHistory>
<IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName>
<CopyrightYear>1995</CopyrightYear>
</IssueCopyright>
</IssueInfo>
<Article ID="Art14"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF00202176</ArticleID>
<ArticleDOI>10.1007/BF00202176</ArticleDOI>
<ArticleSequenceNumber>14</ArticleSequenceNumber>
<ArticleTitle Language="En">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</ArticleTitle>
<ArticleCategory>Pharmacoepidemiology and Disposition</ArticleCategory>
<ArticleFirstPage>71</ArticleFirstPage>
<ArticleLastPage>75</ArticleLastPage>
<ArticleHistory><RegistrationDate><Year>2004</Year>
<Month>7</Month>
<Day>15</Day>
</RegistrationDate>
<Received><Year>1994</Year>
<Month>5</Month>
<Day>20</Day>
</Received>
<Accepted><Year>1994</Year>
<Month>10</Month>
<Day>21</Day>
</Accepted>
</ArticleHistory>
<ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName>
<CopyrightYear>1995</CopyrightYear>
</ArticleCopyright>
<ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant>
<AbstractGrant Grant="OpenAccess"></AbstractGrant>
<BodyPDFGrant Grant="Restricted"></BodyPDFGrant>
<BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant>
<BibliographyGrant Grant="Restricted"></BibliographyGrant>
<ESMGrant Grant="Restricted"></ESMGrant>
</ArticleGrants>
<ArticleContext><JournalID>228</JournalID>
<VolumeIDStart>48</VolumeIDStart>
<VolumeIDEnd>48</VolumeIDEnd>
<IssueIDStart>1</IssueIDStart>
<IssueIDEnd>1</IssueIDEnd>
</ArticleContext>
</ArticleInfo>
<ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1 Aff2" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>E.</GivenName>
<FamilyName>Lunell</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>L.</GivenName>
<FamilyName>Molander</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName>
<FamilyName>Andersson</FamilyName>
</AuthorName>
</Author>
<Affiliation ID="Aff1"><OrgName>Pharmacia Research Laboratories</OrgName>
<OrgAddress><Street>Karl XI gatan 4</Street>
<Postcode>S-222 20</Postcode>
<City>Lund</City>
<Country>Sweden</Country>
</OrgAddress>
</Affiliation>
<Affiliation ID="Aff2"><OrgDivision>Department of Clinical Pharmacology</OrgDivision>
<OrgName>University Hospital</OrgName>
<OrgAddress><City>Lund</City>
<Country>Sweden</Country>
</OrgAddress>
</Affiliation>
<Affiliation ID="Aff3"><OrgDivision>Department of Oto-rhino-laryngology</OrgDivision>
<OrgName>University Hospital</OrgName>
<OrgAddress><City>Lund</City>
<Country>Sweden</Country>
</OrgAddress>
</Affiliation>
</AuthorGroup>
<Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading>
<Para>The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state.</Para>
<Para>Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of C<Subscript>max</Subscript>
, AUC and t<Subscript>max</Subscript>
 were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the t<Subscript>max</Subscript>
 ratio to 1.72.</Para>
<Para>The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</Para>
</Abstract>
<KeywordGroup Language="En"><Heading>Key words</Heading>
<Keyword>Nicotine</Keyword>
<Keyword>Rhinitis</Keyword>
<Keyword>pharmacokinetics</Keyword>
<Keyword>nasal spray</Keyword>
<Keyword>xylometazoline</Keyword>
<Keyword>drug interaction</Keyword>
</KeywordGroup>
</ArticleHeader>
<NoBody></NoBody>
</Article>
</Issue>
</Volume>
</Journal>
</Publisher>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
</titleInfo>
<name type="personal" displayLabel="corresp"><namePart type="given">E.</namePart>
<namePart type="family">Lunell</namePart>
<affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</affiliation>
<affiliation>Department of Clinical Pharmacology, University Hospital, Lund, Sweden</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">L.</namePart>
<namePart type="family">Molander</namePart>
<affiliation>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund, Sweden</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">Andersson</namePart>
<affiliation>Department of Oto-rhino-laryngology, University Hospital, Lund, Sweden</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>Springer-Verlag</publisher>
<place><placeTerm type="text">Berlin/Heidelberg</placeTerm>
</place>
<dateCreated encoding="w3cdtf">1994-05-20</dateCreated>
<dateIssued encoding="w3cdtf">1995-03-01</dateIssued>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<abstract lang="en">Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</abstract>
<note>Pharmacoepidemiology and Disposition</note>
<subject lang="en"><genre>Key words</genre>
<topic>Nicotine</topic>
<topic>Rhinitis</topic>
<topic>pharmacokinetics</topic>
<topic>nasal spray</topic>
<topic>xylometazoline</topic>
<topic>drug interaction</topic>
</subject>
<relatedItem type="host"><titleInfo><title>European Journal of Clinical Pharmacology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Eur J Clin Pharmacol</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<originInfo><publisher>Springer</publisher>
<dateIssued encoding="w3cdtf">1995-03-01</dateIssued>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<subject><genre>Biomedicine</genre>
<topic>Pharmacology/Toxicology</topic>
</subject>
<identifier type="ISSN">0031-6970</identifier>
<identifier type="eISSN">1432-1041</identifier>
<identifier type="JournalID">228</identifier>
<identifier type="IssueArticleCount">20</identifier>
<identifier type="VolumeIssueCount">6</identifier>
<part><date>1995</date>
<detail type="volume"><number>48</number>
<caption>vol.</caption>
</detail>
<detail type="issue"><number>1</number>
<caption>no.</caption>
</detail>
<extent unit="pages"><start>71</start>
<end>75</end>
</extent>
</part>
<recordInfo><recordOrigin>Springer-Verlag, 1995</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="istex">7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C</identifier>
<identifier type="ark">ark:/67375/1BB-PJ4Q91WT-1</identifier>
<identifier type="DOI">10.1007/BF00202176</identifier>
<identifier type="ArticleID">BF00202176</identifier>
<identifier type="ArticleID">Art14</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag, 1995</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource>
<recordOrigin>Springer-Verlag, 1995</recordOrigin>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000178 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000178 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C
   |texte=   Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
}}

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021

	Serveur d'exploration Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Covid

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri